Projects related to 6-2019-6708

Results Found (24)
Technology NameBriefcaseLead Researcher
Background Most active pharmaceutical ingredients (APIs) are not suitable for “passive” loading into nano-liposomes. The desired concentration in the nano-liposomes is hard to achieve. Consequently, the therapeutic efficacy in humans is not ...
More
Goldblum Amiram
Background Emulsification in aqueous media is not effective for the encapsulation of hydrophilic drugs. Peptides and proteins may deteriorate when exposed to aqueous-organic interfaces Neuropeptides are potent CNS neuromodulators and have many ...
More
Domb Abraham
Background Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) are leading causes of blindness in the Western world. Both are characterized by pathological angiogenesis in the various eye structures. With high prevalence  in  ...
More
Willner Itamar
  Additional information will be provided upon request
More
Domb Abraham
Background  Micro-emulsions are formed more or less spontaneously when their components are brought into contact.  They have been the only successful delivery systems for certain types of pharmaceutical compounds, particularly compounds such as ...
More
Domb Abraham
Background Emulsification in aqueous media is not effective for the encapsulation of hydrophilic drugs. Peptides and proteins may deteriorate when exposed to aqueous-organic interfaces Neuropeptides are potent CNS neuromodulators and have many ...
More
Domb Abraham
Background The release of targeted drugs is often achieved by attaching the drug load to a carrier through specific peptide sequences which are cleaved by proteases that are highly expressed at the desired location. Cathepsins proteases, ...
More
Blum Galia
Background Peptides are key players in a variety of physiological and pathological processes and play very important roles in modulating various cell functions. One of the most important challenges developing peptide drugs is the lack of ...
More
Gilon Chaim
Background Multiple strategies exist for the targeted treatment of different cell pathologies. One ongoing challenge is the introduction of therapeutic molecules into cells. Current approaches rely on viral vectors, electroporation, or carriers. ...
More
Shenhar Roy
Background The physical size of protein drugs and their susceptibility to degradation are key determinates that make them more dependent on drug delivery technologies. However formulating protein delivery systems so that they maintain their ...
More
Barenholz Yechezkel
  Current Development Stage TRL 9 Ready for mass production   Our Innovation Pouch drug delivery system (web- like films) for dermal, transdermal and nail  administration of drugs and actives for various treatments Applied to the nail or ...
More
Touitou Elka
  Categories Cannabinoid Administration, Formulation, Drug Delivery, Novel Carriers, Transdermal Formulation, Nasal Formulation, Oral formulation Development Stage In-vivo proof of concept Patent Status Several patent applications – new ...
More
Touitou Elka
Category Prolonged release oral tablets    Keywords Cannabinoids, Cannabis, tablets, oral administration  Application In recent years, the medical use of cannabis and its derivatives has become widely accepted in the medical profession.  IN ...
More
Friedman Michael
BackgroundAccording to the World Health Organization approximately 422 million people currently suffer from diabetes. Type-I diabetes patients are characterized by their pancreas β-cells dysfunction and thereby absence of insulin secretion. ...
More
Willner Itamar
Background: Dental disorders occur when there are changes in oral hygiene, diet, medicaments or age. Our Innovation Novel dental coating that delivers therapeutics over time, as required, in response to sensed changes in acidic/basic conditions ...
More
Friedman Michael
Background Valproic acid (VPA) is a first line antiepileptic and CNS drug (Epilepsy, neuropathic pain, bipolar disorders etc) Multivalent action of VPA is highly advantageous, promising improved efficacy with reduced side effects for ...
More
Bialer Meir
  Additional information will be provided upon request
More
Domb Abraham
Category LifeSciences and BioTechnology    Keywords Natural compounds, Synthetic compounds, Neurodegenerative disorders Current development stage For Pharmaceutical development: TRL4 - POC & Safety of candidate drug formulation is ...
More
Tsvelikhovsky Dmitry
Background Parkinson’s Disease (PD) is a progressive neurodegenerative disease caused by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). As the disease progresses the number of dopaminergic neurons decreases. ...
More
Atlas Daphne
Background  Parkinson disease (PD) is a long-term, progressive neurodegenerative disorder of the central nervous system, which results in motor and non-motor dysfunction. The disease is primarily related to loss of dopaminergic ...
More
Sharon Ronit
  Category LifeSciences and BioTechnology    Keywords Parkinson’s Disease, PD, Dementia, Diagnostic Kit, Diagnostics, Non-Motor Symptoms, mRNA, Circulating RNA Current development stage General list: TRL3 Experimental proof of ...
More
Soreq Hermona
  Category LifeSciences and BioTechnology    Keywords Diagnosis, Alzheimer’s disease, cfDNA, Liquid biopsy, Current development stage General list: TRL3 Experimental proof of concept               Opportunity It is estimated that ...
More
Dor Yuval
ApplicationValproic Acid (VPA) is used alone or with other medications to treat certain types of seizures such as epileptic seizures. It is also used to prevent migraine headaches and to treat mania (episodes of frenzied, abnormally excited ...
More
Bialer Meir